Applications

1714 – National Blood Authority listing for Obizur® (susoctocog alfa) for treatment of bleeding episodes with acquired Haemophilia A

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Referral
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Supported

Application details

Reason for application

Referral from National Blood Authority.

Service or technology in this application

Susoctocog alfa is a treatment used to replace the missing protein needed for blood clotting (Factor VIII), which is less susceptible to being inhibited by autoantibodies than the patient’s own protein. This allows clotting to occur and assists to stop the bleeding. It also allows for the patient’s protein levels to be measured, to assist with guiding dosing and optimising treatment efficacy and safety.

Type: Therapeutic

Medical condition this application addresses

Acquired Haemophilia A is a condition where patients present with spontaneous bleeding despite no history of a bleeding disorder. Patients have the required protein needed for blood clotting, but autoantibodies develop to inhibit this normal function.

Consultation survey and deadlines

  • PASC consultation: Expedited – bypassing PASC
  • MSAC consultation: Closed Friday 10 February 2023

Meetings to consider this application

  • PASC meeting: Bypassing PASC
  • ESC meeting: 9–10 February 2023
  • MSAC meeting: 30–31 March 2023